Non-alcoholic fatty liver disease (NAFLD) is a primary cause of chronic liver disease and cirrhosis. Join host, Geoff Wall, as he evaluates new data on the diagnosis and treatment of NAFLD.
 
The GameChanger
Historical treatment of NAFLD includes beta-blockers, diuretics, and lactulose for hepatic encephalopathy. Newer agents include statins, pioglitazone, and even vitamin E.

Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and Resources
Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review. JAMA. 2023 May 9;329(18):1589-1602. doi: 10.1001/jama.2023.5997. PMID: 37159031.

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
 
CE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the treatment of cirrhosis and subsequent complications
2. Develop treatment recommendations for persons with NAFLD

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-235-H01-P
Initial release date: 6/26/2023
Expiration date: 6/26/2024
Additional CPE details can be found here.

This podcast episode was financially supported through grant funding from Ananda Professional. 

Want to learn more about CBD as an expanded pharmacy service? Join the CBD Academy in the CEimpact App by CLICKING HERE.

Follow CEimpact on Social Media:
LinkedIn
Instagram